|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased α-synuclein levels and mutations in mitochondria-associated proteins both cause familial Parkinson's disease (PD), and synuclein and mitochondria also play central, but poorly understood, roles in the pathogenesis of idiopathic PD.
|
23512373 |
2013 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data demonstrate olfactory deficits in a synuclein fly PD model for exploring olfactory pathology and physiology, and for monitoring PD progression and treatment.
|
24879013 |
2014 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immune alterations in response to extracellular <i>α</i>-synuclein may play a critical role in modulating Parkinson's disease progression.
|
29850629 |
2018 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we report that all three naturally occurring synuclein isoforms (alpha, beta, and gamma-synuclein) are similarly effective inhibitors of PLD2 in vitro, as is the Parkinson's disease-associated mutant A30P.
|
15033366 |
2004 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rats and mice with unilateral damage to the nigrostriatal dopamine system-induced by neurotoxins, such as 6-hydroxydopamine, overexpression of α-synuclein, or injections of toxic synuclein protofibrils-are widely used as experimental models to mimic the loss of dopamine neurons seen in Parkinson's disease.
|
30741691 |
2019 |
|
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Because cortical metabolism is reduced in Parkinson's disease and closely associated with cognitive impairment, and CSF amyloid-<i>β</i> species are reduced and correlate with neuropsychological performance in Parkinson's disease, and amyloid-<i>β</i> release to interstitial fluid may be related to synaptic activity; we hypothesize that synapse dysfunction links cortical hypometabolism, reduced CSF amyloid-<i>β,</i> and presynaptic deposits of <i>α</i>-synuclein.
|
29046879 |
2017 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>The objective of this study was to determine whether there is evidence from quantitative morphometry and spatial pattern analysis to support the hypothesis of anatomical spread of -synuclein in Parkinson's disease dementia (PDD).
|
28430289 |
2017 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aggregation of the protein ɑ-synuclein (ɑS) underlies a range of increasingly common neurodegenerative disorders including Parkinson's disease.
|
28673288 |
2017 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The synuclein family is composed of three members, two of which, α- and β-synuclein, play a major role in the development of synucleinopathies, including Parkinson's disease (PD) as most important movement disorder, dementia with Lewy bodies (DLB) as the second most frequent cause of dementia after Alzheimer's disease and multiple system atrophy.
|
29370097 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The etiology of Parkinson's disease (PD) is linked with cellular inclusions in the <i>substantia nigra pars compacta</i> region of the brain that are enriched in the misfolded presynaptic protein <i>α</i>-synuclein (<i>α</i>S) and death of the dopaminergic neurons.
|
31687080 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neurons ectopically expressing mutant LRRK2 formed inclusion bodies (IBs), retracted neurites, accumulated synuclein, and died prematurely, recapitulating key features of PD.
|
24403142 |
2014 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the attempt to better reproduce the key features of PD, in particular the progressive nature of neurodegeneration, alternative PD models have been developed, based on the genetic and neuropathological links between -synuclein ( -syn) and PD.
|
20522009 |
2010 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
For example, epigenetic alterations of the gene encoding for <i>α</i>-synuclein (<i>SNCA</i>) have been widely explored in both brain and peripheral tissues of Parkinson's disease samples.
|
29849887 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>α</i>-synuclein RT-QuIC in cerebrospinal fluid of LRRK2-linked Parkinson's disease.
|
31211166 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The intrinsically disordered protein β-synuclein is known to inhibit the aggregation of its intrinsically disordered homolog, α-synuclein, which is implicated in Parkinson's disease.
|
29782835 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although a survey of the available databases suggests that there is no human splice form equivalent of rSYN2, thus arguing against a direct role in Lewy body formation and Parkinson's disease, these data nonetheless suggest that modifications of the carboxy-terminal region of -synuclein predispose it to inclusion formation.
|
11959424 |
2002 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Αlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease.
|
26501339 |
2015 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
β-synuclein (βS) is a homologue of α-synuclein (αS), the major protein component of Lewy bodies in patients with Parkinson's disease.
|
26332674 |
2016 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, many Lewy neurites immunopositive for phosphorylated a-synuclein were found in the nerve fascicles of the epicardium in one case examined and in Parkinson's disease cases to a lesser degree.
|
17319280 |
2007 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these data further support a role for beta-synuclein in regulating the conformational state of alpha-synuclein and suggest that this gene transfer approach might have potential for the development of alternative therapies for PD and DLB.
|
15483670 |
2004 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that variants in all 3 members of the synuclein gene family, particularly SNCA and SNCG, affect the risk of developing DLBD and warrant further investigation in larger, pathologically defined data sets as well as clinically diagnosed Parkinson disease/dementia with Lewy bodies case-control series.
|
20697047 |
2010 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plant Extracts and Phytochemicals Targeting <i>α</i>-Synuclein Aggregation in Parkinson's Disease Models.
|
30941047 |
2018 |
|
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results revealed that treatment with 7,8-DHF improved PD model's behavioral performance and reduced dopaminergic neuron loss in the SN and striatum, associated with the activation of TrkB receptors and its signaling cascades, and reduced <i>p</i>-MAPK, <i>p</i>-<i>α</i>-synuclein, and <i>p</i>-tau.
|
30944722 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We are witnessing exciting times, with the first clinical trials being conducted that target synuclein, and bring the hope of novel therapies for patients with PD and their families.
|
31441047 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
As mutations altering alpha-synuclein structure or increasing alpha-synuclein expression level can cause familial forms of PD or related Lewy body disorders, alpha-synuclein is believed to play a central role in the process of neuron toxicity, degeneration and death in "synucleinopathies". beta-synuclein is closely related to alpha-synuclein and has been shown to inhibit alpha-synuclein aggregation and ameliorate alpha-synuclein neurotoxicity.
|
16959793 |
2006 |